Be the first to know!

Sign up now to stay in the know with the latest news and exclusive offers delivered right to your inbox!

Intended for US residents only. For more information, please review our Privacy Statement.

Contact Us


1000 Mylan Blvd.
Canonsburg, PA 15317

Customer Relations:

Mylan Specialty L.P.
800.796.9526 (Main Phone)
304.554.4713 (Fax Number)

Share This Site

More Important Safety Information

Use EpiPen® (epinephrine injection, USP) 0.3 mg or EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors right away when you have an allergic emergency (anaphylaxis). Get emergency medical help right away. You may need further medical attention. Only a healthcare professional should give additional doses of epinephrine if you need more than two injections for a single anaphylactic episode. EpiPen® or EpiPen Jr® should only be injected into the middle of your outer thigh (upper leg), through clothing if necessary. Do not inject into your veins, buttocks, fingers, toes, hands or feet. Hold the leg of young children firmly in place before and during injection to prevent injuries. In case of accidental injection, please seek immediate medical treatment.

Rarely, patients who have used EpiPen® or EpiPen Jr® may develop an infection at the injection site within a few days. Some of these infections can be serious. Call your healthcare professional right away if you have any of the following at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Tell your healthcare professional about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, high blood pressure or heart problems, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your healthcare professional all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you use EpiPen® or EpiPen Jr®.

Common side effects include fast, irregular or “pounding” heartbeat, sweating, nausea or vomiting, breathing problems, paleness, dizziness, weakness, shakiness, headache, feelings of over excitement, nervousness or anxiety. These side effects usually go away quickly if you lie down and rest. Tell your healthcare professional if you have any side effect that bothers you or that does not go away.


EpiPen® and EpiPen Jr®  Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen® and EpiPen Jr® are intended for immediate administration as emergency supportive therapy only. Seek immediate emergency medical help right away.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-796-9526.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Appendix: References

  1. Ahmed DDF, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol Allergy Clin North Am. 2003;23(2):205-219.
  2. Aronson JK. Where name and image meet—the argument for “adrenaline”. National Center for Biotechnology Information. February 12, 2000; 320(7233):506-509. Available at: Accessed: February 27, 2015.
  3. Barnett J, Botting N, Gowland MH, Lucas JS. The strategies that peanut and nut-allergic consumers employ to remain safe when travelling abroad. Clin Transl Allergy. 2012;2:12.
  4. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel.J Allergy Clin Immunol. 2010;126(6):S1-S58.
  5. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;124(6):1549-1555.
  6. Cianferoni A, Muraro A. Food-induced anaphylaxis. Immunol Allergy Clin North Am. 2012;32(2):165-195.
  7. Dinakar C. Anaphylaxis in children: current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep/ 2012;12(6):641-649.
  8. Data on File. IMS Competitive Landscape, 1987-2016. Mylan Specialty LP; 2016.
  9. Data on File, EpiPen Pens October 2012-July 2017, Mylan Specialty LP; 2017.
  10. Data on file: Mylan Specialty L.P. EpiPen 4 Schools Summary (6/14/2017).
  11. Eigenmann PA, Zamora SA. An internet-based survey on the circumstances of food-induced reactions following the diagnosis of IgE-mediated food allergy. Allergy. 2002.57(5):449-453.
  12. Epinephrine Injection, USP Auto-Injector combined PI & PPI. Morgantown, WV: Mylan Specialty LP; 2017.
  13. EpiPen combined PI & PPI. Morgantown, WV: Mylan Specialty LP; 2017.
  14. FAA [US Department of Transportation, Federal Aviation Administration]. Management of passengers who may be sensitive to allergens. Advisory Circular No 121-36. December 3, 2002.
  15. FARE [Food Allergy Research & Education] Food Allergy Facts and Statistics for the US.
  16. FAAN [Food Allergy and Anaphylaxis Network]. Welcoming Guests with Food Allergies. Fairfax, VA: FAAN; 2001.
  17. FDA [U.S. Department of Health and Human Services Food and Drug Administration]. Drugs@FDA: FDA Approved Drug Products: EpiPen. Accessed July 19, 2017.
  18. FDA [U.S. Department of Health and Human Services Food and Drug Administration]. Approved Drug Products With Therapeutic Equivalence Evaluations. 37th ed. Washington, DC: U.S. Department of Health and Human Services; 2017.
  19. FDA [U.S. Department of Health and Human Services Food and Drug Administration]. FDA List of Authorized Generic Drugs. lopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm126389.htm. Accessed July 19, 2017.
  20. Gawlik R, PItsch T, DuBuske L. Anaphylaxis as a Manifestation of Horse Allergy. WOA Journal Immunol. 2009; 2:185-189.
  21. Golden DBK. Insect Sting Anaphylaxis. J Allergy Clin Immunol. 2007; 27(2007):261-272.
  22. Golden DBK, Moffitt J, Nicklas RA. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127(4):852-854, 854.e1-854.e23.
  23. Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9-e17.
  24. Hosey RG, Carek PJ, Goo A. Exercise-induced anaphylaxis and urticaria. Am Fam Physician. 2001;64(8):1367-1372,1374.
  25. Kim JS, Sicherer SH. Living with food allergy: allergen avoidance. Pediatr Clin N Am. 2011;58(2):459-470.
  26. Leonard SA, Weiss C, Furlong TJ, Sicherer SH. Food allergies affect vacation planning [Abstract 95]. J Allergy Clin Immunol. 2009;123(2)(suppl):S28. Presented at the 2009 AAAAI Meeting, Washington DC, March 13-17, 2009.
  27. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477-480,480.e1-480.e42.
  28. Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2010;126(4):798-806.
  29. McMorris MS, Furlong TJ, Greenhawt MJ. Self-reported allergic reactions to peanuts and tree nuts occurring on commercial aircraft. [Abstract 719]. J Allergy Clin Immunol. 2008;121(2):S187. Presented at the 2008 AAAAI Annual Meeting, Philadelphia, PA, March 14 – March 18, 2008.
  30. Miller CWT, Guha B, Krishnaswamy G. Exercise-induced anaphylaxis: a serious but preventable disorder. Physician Sportsmed. 2008;36(1):87-94.
  31. Moses M, Gilchrest C, Schwab NC. Section 504 of the Rehabilitation Act: determining eligibility and implications for school districts. J School Nurs. 2005;21(1):48-58.
  32. Mudd K, Wood Ra. Managing food allergies in schools and camps. Pediatr Clin N Am. 2011;58(2):471-480.
  33. Munoz-Furlong A. Daily coping strategies for patients and their families. Pediatrics. 2003;111(6):1654-1661.
  34. Munoz-Furlong A, Sampson HA. The management of food allergy. In: Metcalfe DD, Sampson HA, Simon RA, Eds. Food Allergy: Adverse Reactions to Foods and Food Additives, 4th Edition. Malden, MA: Blackwell Publishing; 2008:443-460.
  35. Muraro A, Clark A, Beyer K, et al. The management of the allergic child at school: EAACI/GA2LEN Task Force on the allergic child at school. Allergy. 2010;65(6):681-689.
  36. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Report of the NIH Expert Panel on Food Allergy Research. 2006. allergy.aspx. Accessed August 15, 2017.
  37. Nguyen-Luu NU, Ben-Shoshan M, Alizadehfar R, et al. Inadvertent exposures in children with peanut allergy. Pediatr Allergy Immunol. 2012;23(2):133-139.
  38. Park HJ and Kim SH. Factors associated with shock in anaphylaxis. The American Journal of Emergency Medicine. 2012; 30: 1674-1678.
  39. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J Allergy Clin Immunol. 2006;117(2):391-397.
  40. Sheffer AL, Feldweg A, Castells M. Anaphylaxis. In: Holgate ST, Church MK, Lichenstein LM. Allergy. Philadelphia, PA: Elsevier; 2006:167-178.
  41. Sicherer SH, Furlong TJ, DeSimone J, Sampson HA. The US Peanut and Tree Nut Allergy Registry: characteristics of reactions in schools and day care. J Pediatr. 2001;138(4):560-565. Accessed January 9, 2013.
  42. Sicherer SH, Mahr T, Section on Allergy and Immunology. Clinical report—management of food allergy in the school setting. Pediatrics. 2010;126(6):1232-1239.
  43. Simons FER. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2)(suppl 2):S161-S181.
  44. Simons FER. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. 2009;124(4):625-636.
  45. Simons FER, Ardusso LRF, Bilo MB, et al; World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;42(2):13-37.
  46. Simons FER, et al; World Allergy Organization. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014; 7(9): 1-19.
  47. Simons FER, et al; World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. International Archives of Allergy and Immunology. 2013;162:193-204.
  48. Sohail MR, Fischer PR. Health risks to air travelers. Infect Dis Clin North Am. 2005;19(1):67-84.
  49. Sommers TE. Locating a health care provider abroad. In: Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, Whatley AD, Eds. CDC Health Information for International Travel, 2012. [Yellow Book]. New York, NY: Oxford University Press; 2012:119-120. Accessed August 2, 2013.
  50. TSA [US Department of Homeland Security, Transportation Safety Administration]. Disabilities and Medical Condition. Accessed July 19, 2017.
  51. US Census Bureau. Quick Facts: United States. Population estimates, July 1, 2016 (V2016). Accessed July 19, 2017.
  52. US Department of Agriculture. Accommodating Children with Special Dietary Needs in School Nutrition Programs: Guidance for School Food Service Staff. Washington, DC: USDA, Food and Nutrition Service; 2001.
  53. US Department of Justice. A Guide to Disability Rights Laws. Washington, DC: US Department of Justice; July 2009. Accessed August 2, 2013.
  54. Venes D. Taber’s Cyclopedic Medical Dictionary, 23rd Edition. Philadelphia, PA: FA Davis Company; 20017.
  55. Volcheck GW. Clinical Allergy: Diagnosis and Management. Rochester, MN: Mayo Foundation for Medical Education and Research; 2009.
  56. Whatley AD, Marshall CM. Travel health kits. In: Brunette GW, Kozarsky PE, Magill AJ, Shlim DR, Whatley AD, Eds. CDC Health Information for International Travel, 2012. [Yellow Book]. New York, NY: Oxford University Press; 2012:112-116. Accessed January 11, 2013.
EpiPen® & EpiPen Jr® (epinephrine injection, USP) Auto-Injectors 0.3/0.15mg

You are now leaving Mylan Specialty's website.

The website you are about to access is not owned or controlled by Mylan Specialty.